EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Narrow Therapeutic Index Drugs: FDA Experience, Views, and Operations

Mark Donnelly iD, Lanyan Fang, Rajanikanth Madabushi, Hao Zhu, Markham Luke iD, Crystal Canterbury, Bruce Lerman, Paramjeet Kaur, Devvrat Patel, Wanjie Sun, Don Schuirmann, Steven Dinsmore und 2 weitere

Clinical Pharmacology & Therapeutics · 2025-01 · 117 (1) · 116-129

DOI: 10.1002/cpt.3460 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 11.11.2024. Verfasst von Mark Donnelly und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Quantitative Methods and Modeling (DQMM), Office of Research and Standards (ORS), Office of Generic Drugs (OGD), Center for Drug Evaluati…. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Drugs, Generic. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 96 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The U.S. Food and Drug Administration (FDA) has defined narrow therapeutic index (NTI) drugs as “those drugs where small differences in dose or blood concentration may lead to serious therapeutic failures and/or adverse drug reactions that are life‐threatening or result in persistent or significant disability or incapacity.” FDA has undertaken efforts to develop NTI assessment criteria and enhance public confidence in generic NTI drugs through public workshops, research, and post‐marketing surveillance. In 2015, FDA formed the NTI Drug Working Group to develop a consistent approach to identify NTI drugs and resolve NTI‐related scientific and regulatory issues in a transparent and collaborative manner. One key objective of the NTI Drug Working Group is to evaluate potential NTI drugs based on five general characteristics of NTI drugs as highlighted in the case example for theophylline drug products. As of January 5, 2024, there are 33 drug products, with 14 distinct active ingredients, specified as NTI drugs in their respective product‐specific guidances (PSGs) for generic drug development. Future collaborative efforts with other agencies to harmonize the terms and definitions for NTI drugs may help enhance clarity and consistency during the drug development and the regulatory review process.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

United States Food and Drug AdministrationDrugs, GenericUnited StatesHumansDrug ApprovalDrug-Related Side Effects and Adverse ReactionsDrug DevelopmentProduct Surveillance, Postmarketing

Substanzen

Drugs, Generic

Autor:innen und Institutionen

  • Division of Quantitative Methods and Modeling (DQMM), Office of Research and Standards (ORS), Office of Generic Drugs (OGD), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silve…
  • Immediate Office (IO), Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS), CDER, FDA, Silver Spring, Maryland, USA.
  • Division of Pharmacometrics (DPM), OCP, OTS, CDER, FDA, Silver Spring, Maryland, USA.
  • Division of Therapeutic Performance (DTP) I, ORS, OGD, CDER, FDA, Silver Spring, Maryland, USA.
  • Division of Legal and Regulatory Support (DLRS), Office of Generic Drug Policy (OGDP), OGD, CDER, FDA, Silver Spring, Maryland, USA.
  • Division of Bioequivalence (DB) I, Office of Bioequivalence (OB), OGD, CDER, FDA, Silver Spring, Maryland, USA.

ORCID-Profile: Mark Donnelly, Markham Luke, Liang Zhao

Zitieren

APA

Donnelly, M., Fang, L., Madabushi, R., Zhu, H., Luke, M., Canterbury, C., Lerman, B., Kaur, P., Patel, D., Sun, W., Schuirmann, D., Dinsmore, S., Mehta, M., & Zhao, L. (2025). Narrow Therapeutic Index Drugs: FDA Experience, Views, and Operations. Clinical Pharmacology & Therapeutics, 117(1), 116-129. https://doi.org/10.1002/cpt.3460

Vancouver

Donnelly M, Fang L, Madabushi R, Zhu H, Luke M, Canterbury C, et al. Narrow Therapeutic Index Drugs: FDA Experience, Views, and Operations. Clinical Pharmacology & Therapeutics. 2025;117(1):116-129. doi:10.1002/cpt.3460

BibTeX
@article{Donnelly2025,
  author = {Donnelly, Mark and Fang, Lanyan and Madabushi, Rajanikanth and Zhu, Hao and Luke, Markham and Canterbury, Crystal and Lerman, Bruce and Kaur, Paramjeet and Patel, Devvrat and Sun, Wanjie and Schuirmann, Don and Dinsmore, Steven and Mehta, Mehul and Zhao, Liang},
  title = {Narrow Therapeutic Index Drugs: FDA Experience, Views, and Operations},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {117},
  number = {1},
  pages = {116--129},
  doi = {10.1002/cpt.3460}
}
Kostenlos starten →